EMA says Lilly’s Lartruvo should not be prescribed

The product was viewed as an important element in Lilly’s efforts to prop up its oncology franchise after the loss of patent protection for blockbuster Alimta (pemetrexed) in some markets,

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly does have presence in the lung cancer field with Alimta, and as this drug is nearing patent expiry, Loxo should provide the firm with opportunities to seize a share of

Roche’s Tecentriq misses survival mark in frontline NSCLC

Roche’s PD-L1 inhibitor Tecentriq (pemetrexed) was unable to meet the threshold for a significant improvement in overall survival (OS) when added to Eli Lilly’s Alimta (pemetrexed) and platinum

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq. Immunotherapy blockbuster Keytruda has received another boost with the European approval of its use in combination with Lilly’s Alimta plus chemotherapy in ... Compared to those on Alimta and

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]